Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2022 Nov 29

PMID 36444541

Authors

Kangpyo Kim

Jaeho Cho

Ju Hyung Moon

Eui-Hyun Kim

Hong In Yoon

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to evaluate the efficacy of radiation therapy (RT) for recurrent or residual pituitary macroadenoma (PMA) invading extrasellar regions.

Materials And Methods: Patients from 2000 to 2020 who received RT with conventional fractionation for recurrent or residual PMA were included. The patients were divided according to the type of tumor [functioning (fx) or non-fx] and the aim of RT (salvage RT alone, immediate postoperative RT, delayed postoperative RT). Local and biochemical failure-free rates (FFR) were calculated using the Kaplan-Meier method.

Results: With a median follow up of 82 months (IQR; 42-132 months), 36 patients treated with conventional RT (total 45-54 Gy in 1.8 or 2 Gy per fraction) for recurrent or residual PMA were analyzed. The 10-year local FFRs after RT for non-fx and fx tumor were 100% and 74.4%, respectively (=0.047). In the immediate postoperative RT group, the 10-year local FFR was 100%, which was higher than the 90% FFR for salvage RT alone or 80% FFR for the delayed postoperative RT group (overall =0.043, immediate vs. salvage; =0.312, immediate vs. delayed; =0.072). The local FFR was compared according to size of tumor with a cut-off value of 4 cm, and there was no significant difference (10-year local FFR 100% vs. 84.7% for >4 cm vs. <4 cm, =0.320). The extents of extrasellar region invasion were not predictive of local failure after RT. We found no grade ≥3 acute toxicities or newly developed visual impairments as a late toxicity of RT.

Conclusion: Conventional RT is safe and effective for the local control of recurrent or residual PMA. Our data suggest that immediate postoperative RT can be beneficial in recurrent or residual PMA, although further studies to evaluate risk factors of treatment failure in terms of treatment and disease characteristics are required.

References

Minniti G, Clarke E, Scaringi C, Maurizi Enrici R . Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother. 2016; 21(4):370-8. PMC: 4899479. DOI: 10.1016/j.rpor.2014.09.004. View

Ben-Shlomo A, Cooper O . Silent corticotroph adenomas. Pituitary. 2018; 21(2):183-193. DOI: 10.1007/s11102-018-0864-8. View

Iglesias P, Berrocal V, Diez J . Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine. 2018; 61(3):407-421. DOI: 10.1007/s12020-018-1645-x. View

Scheick S, Amdur R, Kirwan J, Morris C, Mendenhall W, Roper S . Long-term Outcome After Fractionated Radiotherapy for Pituitary Adenoma: The Curse of the Secretory Tumor. Am J Clin Oncol. 2014; 39(1):49-54. DOI: 10.1097/COC.0000000000000014. View

Dekkers O, Pereira A, Roelfsema F, Voormolen J, Neelis K, Schroijen M . Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006; 91(5):1796-801. DOI: 10.1210/jc.2005-2552. View

Nishioka H, Inoshita N . New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol. 2018; 35(2):57-61. DOI: 10.1007/s10014-017-0307-7. View

Surawicz T, McCarthy B, Kupelian V, Jukich P, Bruner J, Davis F . Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol. 2001; 1(1):14-25. PMC: 1919458. DOI: 10.1093/neuonc/1.1.14. View

Sheehan J, Lee C, Bodach M, Tumialan L, Oyesiku N, Patil C . Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas. Neurosurgery. 2016; 79(4):E539-40. DOI: 10.1227/NEU.0000000000001385. View

Pomeraniec I, Dallapiazza R, Xu Z, Jane Jr J, Sheehan J . Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg. 2015; 125(1):202-12. DOI: 10.3171/2015.5.JNS15581. View

10.

Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea M, Delfini R . Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol. 2007; 68(5):513-8. DOI: 10.1016/j.surneu.2007.05.057. View

11.

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V . European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2017; 178(1):G1-G24. DOI: 10.1530/EJE-17-0796. View

12.

Minniti G, Scaringi C, Poggi M, Rea M, Trillo G, Esposito V . Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015; 172(4):433-41. DOI: 10.1530/EJE-14-0872. View

13.

OSullivan E, Woods C, Glynn N, Behan L, Crowley R, OKelly P . The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2009; 71(5):709-14. DOI: 10.1111/j.1365-2265.2009.03583.x. View

14.

Forster N, Warnick R, Takiar V, Pater L, Breneman J . Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. J Neurooncol. 2018; 138(2):335-340. DOI: 10.1007/s11060-018-2801-0. View

15.

Ronson B, Schulte R, Han K, Loredo L, Slater J, Slater J . Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys. 2005; 64(2):425-34. DOI: 10.1016/j.ijrobp.2005.07.978. View

16.

Saeger W, Koch A . Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors. Exp Clin Endocrinol Diabetes. 2021; 129(3):146-156. DOI: 10.1055/a-1310-7900. View

17.

Erridge S, Conkey D, Stockton D, Strachan M, Statham P, Whittle I . Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009; 93(3):597-601. DOI: 10.1016/j.radonc.2009.09.011. View

18.

Webb K, Laurent J, Okonkwo D, Lopes M, Vance M, Laws Jr E . Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery. 2003; 53(5):1076-84. DOI: 10.1227/01.neu.0000088660.16904.f7. View

19.

Bradley K, Wass J, Turner H . Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf). 2003; 58(1):59-64. DOI: 10.1046/j.1365-2265.2003.01674.x. View

20.

Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G . Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients. Neurol Sci. 2004; 25(5):251-6. DOI: 10.1007/s10072-004-0351-z. View